Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A group of slowly progressive inherited disorders affecting motor and sensory peripheral nerves. Subtypes include HMSNs I-VII. HMSN I and II both refer to CHARCOT-MARIE-Tooth DISEASE. HMSN III refers to hypertrophic neuropathy of infancy. HMSN IV refers to REFSUM DISEASE. HMSN V refers to a condition marked by a hereditary motor and sensory neuropathy associated with spastic paraplegia (see SPASTIC PARAPLEGIA, HEREDITARY). HMSN VI refers to HMSN associated with an inherited optic atrophy (OPTIC ATROPHIES, HEREDITARY), and HMSN VII refers to HMSN associated with retinitis pigmentosa. (From Adams et al., Principles of Neurology, 6th ed, p1343)
Biomarker and diagnostic research for hereditary motor and sensory neuropathy has been reported in the published literature.
No clinical trials have been registered for hereditary motor and sensory neuropathy.
30 publications have been identified in PubMed for hereditary motor and sensory neuropathy. Research spans Basic Science / Preclinical (30%), Review / Meta-Analysis (27%), and Case Report / Case Series (23%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 9 | 30% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 8:42 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries
8 |
27% |
Patient case studies | 7 | 23% |
Testing and diagnosis research | 2 | 7% |
Disease patterns and progression | 2 | 7% |
New treatment approaches | 2 | 7% |
Gupta S (2026). [PMID: 42083783](https://pubmed.ncbi.nlm.nih.gov/42083783/). *Ann Afr Med*. [Case Report / Case Series]
Goret M (2026). [PMID: 41683892](https://pubmed.ncbi.nlm.nih.gov/41683892/). *International journal of molecular sciences*. [Gene Therapy / Novel Therapeutics]
Kaya Keles CS (2026). [PMID: 41850006](https://pubmed.ncbi.nlm.nih.gov/41850006/). *Journal of biomechanics*. [Basic Science / Preclinical]
Subbotin D (2026). [PMID: 41888341](https://pubmed.ncbi.nlm.nih.gov/41888341/). *Mol Genet Genomic Med*. [Review / Meta-Analysis]
Loder AK (2026). [PMID: 41338459](https://pubmed.ncbi.nlm.nih.gov/41338459/). *The Journal of biological chemistry*. [Basic Science / Preclinical]
Rashed HR (2026). [PMID: 41335010](https://pubmed.ncbi.nlm.nih.gov/41335010/). *Muscle & nerve*. [Diagnostic / Biomarker]
Goret M (2025). [PMID: 40042903](https://pubmed.ncbi.nlm.nih.gov/40042903/). *Proceedings of the National Academy of Sciences of the United States of America*. [Gene Therapy / Novel Therapeutics]
Komilova NR (2025). [PMID: 39918771](https://pubmed.ncbi.nlm.nih.gov/39918771/). *Cellular and molecular life sciences : CMLS*. [Basic Science / Preclinical]
Shumeri E (2025). [PMID: 40588830](https://pubmed.ncbi.nlm.nih.gov/40588830/). *Journal of the peripheral nervous system : JPNS*. [Basic Science / Preclinical]
Castoro R (2025). [PMID: 41161998](https://pubmed.ncbi.nlm.nih.gov/41161998/). *Neurologic clinics*. [Review / Meta-Analysis]